0RAE Stock Chart & Stats
€0.69
€0.00(0.00%)
At close: 4:00 PM EDT
€0.69
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.30 - €1.19
Previous CloseN/A
Volume4.00
Average Volume (3M)7.26K
Market Cap
€30.99M
Enterprise Value€78.49
Total Cash (Recent Filing)€4.72M
Total Debt (Recent Filing)€12.24M
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding96,884,340
10 Day Avg. Volume17,850
30 Day Avg. Volume7,260
Financial Highlights & Ratios
PEG Ratio1.15
Price to Book (P/B)-13.62
Price to Sales (P/S)0.00
P/FCF Ratio-9.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.14
Revenue Forecast (FY)€4.05M
Bulls Say, Bears Say
Bulls Say
Biological Technology PlatformA platform built around Willaertia magna gives Amoéba a defined biological technology base for biocontrol and biofertilizer products. Positioning these solutions as alternatives to conventional chemical inputs aligns the business with ongoing demand for biological crop and plant-health options.
Multiple Commercialization RoutesThe model can monetize the same technology through finished products, formulated actives, licensing, royalties, milestones and collaborations. This gives Amoéba several routes to commercialize its platform and potentially extend market access beyond direct product sales when approvals and partners are available.
Recent Loss And Cash-flow ImprovementAlthough still negative, the latest trajectory contains limited evidence of improvement: 2025 losses narrowed versus 2023, while free cash flow improved versus 2024. If sustained, this could reduce the pace of deterioration, but it has not yet produced sustainable profitability or cash generation.
Bears Say
Revenue Collapse And Persistent LossesRevenue effectively fell to zero in 2025 after only a small 2024 base, while EBIT and net income remained deeply negative. This combination shows the commercial model has not yet reached meaningful scale, making near-term operating leverage and durable margin development unproven.
Persistent Cash BurnOperating cash flow has been negative every year, and free cash flow also remained negative, reaching about -€7.4m in 2025. Continued cash burn reduces self-funding capacity and leaves ongoing product development and investment dependent on external financing.
Negative Equity And Rising DebtNegative equity across 2023–2025 coincided with debt rising from about €2.4m in 2022 to €12.2m in 2025, while assets declined. The resulting leverage and weaker asset base constrain financial flexibility and increase refinancing pressure as losses continue.
Amoeba SA News
0RAE FAQ
What was Amoeba SA’s price range in the past 12 months?
Amoeba SA lowest share price was €0.30 and its highest was €1.19 in the past 12 months.
What is Amoeba SA’s market cap?
Amoeba SA’s market cap is €30.99M.
When is Amoeba SA’s upcoming earnings report date?
Amoeba SA’s upcoming earnings report date is Apr 01, 2027 which is in 179 days.
How were Amoeba SA’s earnings last quarter?
Amoeba SA released its earnings results on Sep 24, 2026. The company reported -€0.095 earnings per share for the quarter.
Is Amoeba SA overvalued?
According to Wall Street analysts Amoeba SA’s price is currently Overvalued.
Does Amoeba SA pay dividends?
Amoeba SA does not currently pay dividends.
What is Amoeba SA’s EPS estimate?
Amoeba SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Amoeba SA have?
Amoeba SA has 96,884,340 shares outstanding.
What happened to Amoeba SA’s price movement after its last earnings report?
Amoeba SA reported an EPS of -€0.095 in its last earnings report. Following the earnings report the stock price went down -7.905%.
Which hedge fund is a major shareholder of Amoeba SA?
Currently, no hedge funds are holding shares in GB:0RAE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Amoeba SA
Amoéba S.A. focuses on the development and commercialization of anti-microbial and anti-fungal products. The company's primary innovation centers on harnessing the unique properties of the Willaertia magna C2c Maky amoeba, which it is applying across various fields. These applications are designed to mitigate biological risks in critical areas like water purification, the treatment of human injuries, and safeguarding agricultural crops. Established in 2010, Amoéba S.A. is based in Chassieu, France.